Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy

Hexavalent (HV) vaccination is a priority for newborn protection and in Italy is included in the National Immunization Plan with a three doses cycle at 61, 121 and 301 days of age. A retrospective clinical study has been conducted to evaluate real life clinical practice of HV vaccination in the four...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2022-11, Vol.18 (6), p.2141998-2141998
Main Authors: Costantino, Claudio, Cimino, Livia, Bonaccorso, Nicole, Conforto, Arianna, Sciortino, Martina, Blangiardi, Francesco, Bosco, Girolama, Canzoneri, Gaspare, Casuccio, Nicolò, Collura, Calogero, Cuccia, Mario, Furnari, Roberto, Genovese, Pietro, Gucciardi, Giovanni, Randazzo, Maria Angela, Taranto, Gino Enzo, Palermo, Mario, Vitale, Francesco
Format: Article
Language:English
Subjects:
Child
co-administration
Diphtheria-Tetanus-Pertussis Vaccine
Haemophilus Vaccines
Hepatitis B Vaccines
Hexavalent vaccine
Humans
Immunization Schedule
Infant
Infant, Newborn
interchangeability
Licensed Vaccines
Poliovirus Vaccine, Inactivated
Public Health
real-life vaccination
Retrospective Studies
Sicily
Vaccination - methods
vaccination coverage
Vaccines, Combined
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hexavalent (HV) vaccination is a priority for newborn protection and in Italy is included in the National Immunization Plan with a three doses cycle at 61, 121 and 301 days of age. A retrospective clinical study has been conducted to evaluate real life clinical practice of HV vaccination in the fourth most populous Italian Region. Data on the completion of the HV cycle, on the interchangeability between the two HV adopted in 2016-2017 (DTaP3-IPV-HB/Hib) and 2018-2019 (DTaP5-IPV-HB-Hib) and on the use above the established age, were collected in five Sicilian Local Health Authorities. Data showed an average 91.5% completion of the vaccination cycle at 24 months of age. The average age of administration was significantly higher in children who switched between the two hexavalent vaccines compared to those who completed the vaccination cycle with the same product (p-value 36 months) significantly after the introduction of mandatory vaccination in Italy (p-value
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2022.2141998